Whole-genome sequencing (WGS) of experimental breast cancer models and selected primary and relapsed tumor samples revealed that active APOBEC3 mutations contribute to resistance against endocrine and targeted therapies, primarily through RB1 mutations, leading to its functional impairment [69]. The gene discussed is RB1; the disease is breast carcinoma.